CAR T- and NK-cell therapy for acute myeloid leukaemia
International Immunology · 03.11.2026
DOI: 10.1093/intimm/dxag056 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunology, online erschienen am 03.11.2026. Verfasst von Shunya Ikeda und 1 weiteren Autor:innen. Beteiligte Einrichtung: World Premier International Immunology Frontier Research Center, The University of Osaka, Suita, Japan. Die Arbeit nennt 54 Literaturangaben.
Abstract (Originalsprache)
Adoptive cell therapy has emerged as a powerful approach for treating haematologic malignancies. Among these strategies, chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable clinical efficacy, especially for treating B-cell malignancies. Several CAR T-cell products have been approved for clinical use. Additionally, CAR-engineered natural killer (CAR NK) cells have recently been developed and have shown promising results in clinical trials for treating B-cell malignancies. However, developing CAR T- or NK-cell therapies for acute myeloid leukaemia (AML) has been challenging due to the lack of AML-specific antigens that are not expressed by normal haematopoietic cells. Recently, we developed CAR T- and CAR NK-cell therapies targeting mismatched human leukocyte antigen (HLA)-DRB1 molecules in patients who have undergone allogeneic haematopoietic cell transplantation (allo-HCT). This review summarizes the current status of AML therapy, discusses the challenges of identifying suitable CAR targets, and introduces CAR T- and CAR NK-cell strategies targeting mismatched HLA-DRB1 molecules for treating relapsed AML after allo-HCT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- World Premier International Immunology Frontier Research Center, The University of Osaka, Suita, Japan.
- Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, Japan.
- Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka, Suita, Japan.
- Center for Infectious Disease Education and Research, The University of Osaka, Suita, Japan.
Zitieren
APA
Ikeda, S., & Hosen, N. (2026). CAR T- and NK-cell therapy for acute myeloid leukaemia. International Immunology. https://doi.org/10.1093/intimm/dxag056
Vancouver
Ikeda S, Hosen N. CAR T- and NK-cell therapy for acute myeloid leukaemia. International Immunology. 2026. doi:10.1093/intimm/dxag056
BibTeX
@article{Ikeda2026,
author = {Ikeda, Shunya and Hosen, Naoki},
title = {CAR T- and NK-cell therapy for acute myeloid leukaemia},
journal = {International Immunology},
year = {2026},
doi = {10.1093/intimm/dxag056}
}
EUVIMED